Cargando…

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy

The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single drug therapy. Reprogramming of the RTK network...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goltsov, Alexey, Deeni, Yusuf, Khalil, Hilal S., Soininen, Tero, Kyriakidis, Stylianos, Hu, Huizhong, Langdon, Simon P., Harrison, David J., Bown, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092865/ https://www.ncbi.nlm.nih.gov/pubmed/24918976 http://dx.doi.org/10.3390/cells3020563

Ejemplares similares

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells
por: Khalil, Hilal S., et al.
Publicado: (2016)

NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies
por: Khalil, Hilal S., et al.
Publicado: (2016)

Customizing the Therapeutic Response of Signaling Networks to Promote Antitumor Responses by Drug Combinations
por: Goltsov, Alexey, et al.
Publicado: (2014)

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib
por: Kankia, Ibrahim H., et al.
Publicado: (2017)

Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors
por: Kankia, Ibrahim H., et al.
Publicado: (2021)

Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network
por: Lebedeva, Galina, et al.
Publicado: (2012)

Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies
por: Paramasivan, Poornima, et al.
Publicado: (2019)

A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT
por: Bown, James L., et al.
Publicado: (2016)

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition
por: Claas, Allison M., et al.
Publicado: (2018)

Reprogramming signal transduction through a designer receptor tyrosine kinase
por: Kongkrongtong, Tatphon, et al.
Publicado: (2021)

In Silico Screening of Nonsteroidal Anti-Inflammatory Drugs and Their Combined Action on Prostaglandin H Synthase-1
por: Goltsov, Alexey, et al.
Publicado: (2010)

Synthesis and Anti-Proliferative Effects of Mono- and Bis-Purinomimetics Targeting Kinases
por: Bistrović, Andrea, et al.
Publicado: (2017)

Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
por: Aparicio, L. M. A., et al.
Publicado: (2017)

The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming
por: Cunha, Stéphanie, et al.
Publicado: (2014)

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
por: Sewell, J M, et al.
Publicado: (2002)

Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases
por: Tang, Rong, et al.
Publicado: (2022)

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities
por: Kleczko, Emily K., et al.
Publicado: (2018)

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
por: Gotink, Kristy J., et al.
Publicado: (2009)

Three Grand Challenges in High Throughput Omics Technologies
por: Suravajhala, Prashanth, et al.
Publicado: (2022)

Biomarkers for tyrosine kinase inhibitors in renal cell cancer
por: Coupe, Nicholas, et al.
Publicado: (2012)

Tyrosine Kinases in Cancer
por: Blau, Olga, et al.
Publicado: (2015)

Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies
por: Zhao, Yuming, et al.
Publicado: (2021)

URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers
por: Ding, Zhiwen, et al.
Publicado: (2023)

Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
por: Poddubskaya, Elena V., et al.
Publicado: (2018)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021)

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
por: Stern, David F
Publicado: (2000)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn
por: Li, Chuanzhou, et al.
Publicado: (2018)

BY-kinases: Protein tyrosine kinases like no other
por: Hajredini, Fatlum, et al.
Publicado: (2022)

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
por: Allert, Catana, et al.
Publicado: (2022)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

In-vitro Studies of Anti-EGFR Tyrosine Kinase Activity of Thai nutraceutical Plants
por: Semsri, Suwanna, et al.
Publicado: (2020)

The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
por: Castellani, Francesca, et al.
Publicado: (2020)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
por: Chen, Xiaojie, et al.
Publicado: (2022)

Therapeutic effects of axitinib, an anti-angiogenic tyrosine kinase inhibitor, on interstitial cystitis
por: Shin, Jung Hyun, et al.
Publicado: (2023)

Tyrosine kinases in rheumatoid arthritis
por: Okamoto, Hiroshi, et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4gsfam6e0c0cg2dqqsbhcqmpn2